Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16560888 | 1.00 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL26813176 | 1.00 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL29458304 | 0.94 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL22240394 | 0.94 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL29388851 | 0.94 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL16560864 | 0.94 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL16560918 | 0.94 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL29828027 | 0.94 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL18152585 | 0.89 | EPAS1 (0.79) | EPAS1VEGFA | |
| SCHEMBL19180762 | 0.89 | EPAS1 (0.79) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220081407-A1 | METHODS OF PREPARING SUBSTITUTED INDANES | PELOTON THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081407-A1 | METHODS OF PREPARING SUBSTITUTED INDANES | HIF1AN, EGLN2, HIF1A | EPAS1 25/4885VEGFA 1713/4885 |
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | HIF1AN, HIF1A, EGLN2 | EPAS1 18/4885VEGFA 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.